T1	Procedure 15 40	dual antiplatelet therapy
T2	Negation 41 51	other than
T3	Condition 52 71	atrial fibrillation
T4	Condition 0 11	indications
R1	AND Arg1:T4 Arg2:T1	
T5	Condition 75 106	left atrial appendage occlusion
*	OR T3 T5
T6	Temporal 107 132	at the time of enrollment
T7	Mood 136 156	predicted appearance
T8	Temporal 177 209	within the duration of the trial
T9	Condition 215 238	coronary artery disease
T10	Scope 136 209	predicted appearance of such indications within the duration of the trial
*	OR T6 T10
T11	Scope 52 106	atrial fibrillation or left atrial appendage occlusion
R2	Has_negation Arg1:T11 Arg2:T2	
R3	Has_scope Arg1:T4 Arg2:T11	
T12	Scope 107 239	at the time of enrollment or predicted appearance of such indications within the duration of the trial (eg. coronary artery disease)
R4	Has_scope Arg1:T4 Arg2:T12	
R5	Subsumes Arg1:T10 Arg2:T9	
T13	Condition 241 252	indications
T14	Procedure 256 271	anticoagulation
T15	Temporal 272 297	at the time of enrollment
T16	Mood 301 321	predicted appearance
T17	Temporal 342 374	within the duration of the trial
T18	Scope 301 374	predicted appearance of such indications within the duration of the trial
*	OR T15 T18
T19	Condition 380 398	pulmonary embolism
R6	Subsumes Arg1:T18 Arg2:T19	
R7	AND Arg1:T13 Arg2:T14	
T20	Scope 272 399	at the time of enrollment or predicted appearance of such indications within the duration of the trial (eg. pulmonary embolism)
R8	Has_scope Arg1:T13 Arg2:T20	
T21	Drug 418 429	clopidogrel
T22	Drug 433 453	acetylsalicylic acid
T23	Condition 407 414	allergy
*	OR T21 T22
T24	Non-representable 454 483	precluding its administration
T25	Scope 418 453	clopidogrel or acetylsalicylic acid
R9	Has_scope Arg1:T23 Arg2:T25	
T26	Condition 543 564	coagulation disorders
T27	Condition 566 580	poor tolerance
T28	Observation 587 609	technical difficulties
T29	Procedure 626 658	transesophageal echocardiography
*	OR T27 T28
T30	Scope 566 609	poor tolerance of or technical difficulties
R10	AND Arg1:T30 Arg2:T29	
T31	Measurement 660 675	peridevice leak
T32	Value 676 680	>5mm
T33	Procedure 684 722	transesophageal echocardiography study
R11	Has_value Arg1:T31 Arg2:T32	
R12	AND Arg1:T33 Arg2:T31	
T34	Condition 745 765	left atrial thrombus
T35	Procedure 769 801	transesophageal echocardiography
T36	Procedure 835 864	left atrial appendage closure
T37	Temporal 818 864	after successful left atrial appendage closure
T38	Reference_point 824 864	successful left atrial appendage closure
T39	Qualifier 824 834	successful
R13	Has_qualifier Arg1:T36 Arg2:T39	
R14	multi Arg1:T37 Arg2:T36	
R15	Has_index Arg1:T37 Arg2:T38	
T40	Temporal 869 886	before enrollment
T41	Reference_point 876 886	enrollment
R16	AND Arg1:T35 Arg2:T34	
T42	Scope 818 886	after successful left atrial appendage closure but before enrollment
R17	Has_scope Arg1:T35 Arg2:T42	
T43	Observation 888 903	life expectancy
T44	Value 907 925	less than 18months
R18	Has_value Arg1:T43 Arg2:T44	
T45	Competing_trial 927 1043	participation in other clinical studies with experimental therapies at the time of enrollment and preceding 3 months
T46	Condition 1045 1067	chronic kidney disease
T47	Qualifier 1068 1076	stage IV
T48	Qualifier 1068 1073;1081 1082	stage V
*	OR T48 T47
T49	Scope 1068 1082	stage IV and V
R19	Has_scope Arg1:T46 Arg2:T49	
T50	Person 1084 1089	women
T51	Condition 1098 1106	pregnant
T52	Observation 1110 1124	breast feeding
T53	Pregnancy_considerations 1084 1277	women who are pregnant or breast feeding; women of childbearing potential who do not consent to apply at least to methods of contraception. This criterion does not apply to postmenopausal women
*	OR T51 T52
